Cargando…
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines
BACKGROUND: Doxorubicin (DOX) is widely used in both human and veterinary oncology although the onset of multidrug resistance (MDR) in neoplastic cells often leads to chemotherapy failure. Better understanding of the cellular mechanisms that circumvent chemotherapy efficacy is paramount. The aim of...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814552/ https://www.ncbi.nlm.nih.gov/pubmed/33461558 http://dx.doi.org/10.1186/s12917-020-02709-5 |
_version_ | 1783638077965598720 |
---|---|
author | Levi, Michela Salaroli, Roberta Parenti, Federico De Maria, Raffaella Zannoni, Augusta Bernardini, Chiara Gola, Cecilia Brocco, Antonio Marangio, Asia Benazzi, Cinzia Muscatello, Luisa Vera Brunetti, Barbara Forni, Monica Sarli, Giuseppe |
author_facet | Levi, Michela Salaroli, Roberta Parenti, Federico De Maria, Raffaella Zannoni, Augusta Bernardini, Chiara Gola, Cecilia Brocco, Antonio Marangio, Asia Benazzi, Cinzia Muscatello, Luisa Vera Brunetti, Barbara Forni, Monica Sarli, Giuseppe |
author_sort | Levi, Michela |
collection | PubMed |
description | BACKGROUND: Doxorubicin (DOX) is widely used in both human and veterinary oncology although the onset of multidrug resistance (MDR) in neoplastic cells often leads to chemotherapy failure. Better understanding of the cellular mechanisms that circumvent chemotherapy efficacy is paramount. The aim of this study was to investigate the response of two canine mammary tumour cell lines, CIPp from a primary tumour and CIPm, from its lymph node metastasis, to exposure to EC50((20h)) DOX at 12, 24 and 48 h of treatment. We assessed the uptake and subcellular distribution of DOX, the expression and function of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), two important MDR mediators. To better understand this phenomenon the effects of DOX on the cell cycle and Ki67 cell proliferation index and the expression of p53 and telomerase reverse transcriptase (TERT) were also evaluated by immunocytochemistry (ICC). RESULTS: Both cell lines were able to uptake DOX within the nucleus at 3 h treatment while at 48 h DOX was absent from the intracellular compartment (assessed by fluorescence microscope) in all the surviving cells. CIPm, originated from the metastatic tumour, were more efficient in extruding P-gp substrates. By ICC and qRT-PCR an overall increase in both P-gp and BCRP were observed at 48 h of EC50((20h)) DOX treatment in both cell lines and were associated with a striking increase in the percentage of p53 and TERT expressing cells by ICC. The cell proliferation fraction was decreased at 48 h in both cell lines and cell cycle analysis showed a DOX-induced arrest in the S phase for CIPp, while CIPm had an increase in cellular death without arrest. Both cells lines were therefore composed by a fraction of cells sensible to DOX that underwent apoptosis/necrosis. CONCLUSIONS: DOX administration results in interlinked modifications in the cellular population including a substantial effect on the cell cycle, in particular arrest in the S phase for CIPp and the selection of a subpopulation of neoplastic cells bearing MDR phenotype characterized by P-gp and BCRP expression, TERT activation, p53 accumulation and decrease in the proliferating fraction. Important information is given for understanding the dynamic and mechanisms of the onset of drug resistance in a neoplastic cell population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-020-02709-5. |
format | Online Article Text |
id | pubmed-7814552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78145522021-01-19 Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines Levi, Michela Salaroli, Roberta Parenti, Federico De Maria, Raffaella Zannoni, Augusta Bernardini, Chiara Gola, Cecilia Brocco, Antonio Marangio, Asia Benazzi, Cinzia Muscatello, Luisa Vera Brunetti, Barbara Forni, Monica Sarli, Giuseppe BMC Vet Res Research Article BACKGROUND: Doxorubicin (DOX) is widely used in both human and veterinary oncology although the onset of multidrug resistance (MDR) in neoplastic cells often leads to chemotherapy failure. Better understanding of the cellular mechanisms that circumvent chemotherapy efficacy is paramount. The aim of this study was to investigate the response of two canine mammary tumour cell lines, CIPp from a primary tumour and CIPm, from its lymph node metastasis, to exposure to EC50((20h)) DOX at 12, 24 and 48 h of treatment. We assessed the uptake and subcellular distribution of DOX, the expression and function of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), two important MDR mediators. To better understand this phenomenon the effects of DOX on the cell cycle and Ki67 cell proliferation index and the expression of p53 and telomerase reverse transcriptase (TERT) were also evaluated by immunocytochemistry (ICC). RESULTS: Both cell lines were able to uptake DOX within the nucleus at 3 h treatment while at 48 h DOX was absent from the intracellular compartment (assessed by fluorescence microscope) in all the surviving cells. CIPm, originated from the metastatic tumour, were more efficient in extruding P-gp substrates. By ICC and qRT-PCR an overall increase in both P-gp and BCRP were observed at 48 h of EC50((20h)) DOX treatment in both cell lines and were associated with a striking increase in the percentage of p53 and TERT expressing cells by ICC. The cell proliferation fraction was decreased at 48 h in both cell lines and cell cycle analysis showed a DOX-induced arrest in the S phase for CIPp, while CIPm had an increase in cellular death without arrest. Both cells lines were therefore composed by a fraction of cells sensible to DOX that underwent apoptosis/necrosis. CONCLUSIONS: DOX administration results in interlinked modifications in the cellular population including a substantial effect on the cell cycle, in particular arrest in the S phase for CIPp and the selection of a subpopulation of neoplastic cells bearing MDR phenotype characterized by P-gp and BCRP expression, TERT activation, p53 accumulation and decrease in the proliferating fraction. Important information is given for understanding the dynamic and mechanisms of the onset of drug resistance in a neoplastic cell population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-020-02709-5. BioMed Central 2021-01-18 /pmc/articles/PMC7814552/ /pubmed/33461558 http://dx.doi.org/10.1186/s12917-020-02709-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Levi, Michela Salaroli, Roberta Parenti, Federico De Maria, Raffaella Zannoni, Augusta Bernardini, Chiara Gola, Cecilia Brocco, Antonio Marangio, Asia Benazzi, Cinzia Muscatello, Luisa Vera Brunetti, Barbara Forni, Monica Sarli, Giuseppe Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines |
title | Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines |
title_full | Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines |
title_fullStr | Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines |
title_full_unstemmed | Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines |
title_short | Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines |
title_sort | doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814552/ https://www.ncbi.nlm.nih.gov/pubmed/33461558 http://dx.doi.org/10.1186/s12917-020-02709-5 |
work_keys_str_mv | AT levimichela doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT salaroliroberta doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT parentifederico doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT demariaraffaella doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT zannoniaugusta doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT bernardinichiara doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT golacecilia doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT broccoantonio doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT marangioasia doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT benazzicinzia doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT muscatelloluisavera doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT brunettibarbara doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT fornimonica doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines AT sarligiuseppe doxorubicintreatmentmodulateschemoresistanceandaffectsthecellcycleintwocaninemammarytumourcelllines |